We are Sorry, This Page doesn't Exist
Heat Biologics stock more than doubles after "positive" trial data of its lung cancer treatment
Shares of Heat Biologics Inc. more than doubled in very active trading Tuesday, after the biopharmaceutical company focused on modulating the immune system reported "positive" in.....»»
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) read more.....»»
Seattle Genetics" stock rises on early FDA nod for breast-cancer drug
Shares of Seattle Genetics Inc. gained 1.0% in trading on Friday after the Food and Drug Administration approved Tukysa for certain patients with HER2-positive breast cancer when given in combination with chemotherapy. The drug has a wholesale.....»»
AstraZeneca shares surge on Phase 3 trial success of lung cancer drug
Shares of AstraZeneca.....»»
Immunomedics doubles after cancer drug trial stops early on "remarkable" results
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merck stock slides as lung-cancer drug misses a study endpoint
Merck & Co. shares slipped in the extended session Monday after the drug maker said that its lung-cancer drug Keytruda did not meet one of its endpoints in a clinical study. Merck shares declined 0......»»
Weeks after IPO, Peninsula drug maker lines up Asian cancer-fighting deal
The South San Francisco company's drug, currently in an early-phase clinical trial, targets types of breast and lung cancers as well as gastric cancer, which Asian drug makers are anxious to tackle......»»
The Daily Biotech Pulse: Roche"s Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) 0 read more.....»»
BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results
- To Submit New Drug Applications ("NDAs") in China for Both Non-Small Cell Lung Cancer ("NSCLC") and Chemotherapy-Induced Neutropenia ("CIN") in Q1.....»»
Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful
Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type......»»
AstraZeneca"s Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study
AstraZeneca plc (NYSE: AZN) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC. read more.....»»
Bristol-Myers Squibb stock falls 5% on lung cancer drug study results
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Bristol-Myers Squibb stock falls on lung cancer drug study result
Bristol-Myers Squ.....»»
AstraZeneca"s Imfinzi Gains Orphan Drug Status for SCLC
The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the mo.....»»
Cytori CFO Resigns, Biotech Restructures In Bid To Focus Resources On Lung Cancer Drug
Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement Friday. read more.....»»
Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or m.....»»
Calithera"s Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy
Calithera Biosciences Inc (NASDAQ: CALA) shares were making a strong upward move Monday following a clinical trial readout from the company. read more.....»»
Lilly"s Cyramza Successful in Phase III First-Line NSCLC Study
Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patien.....»»
Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
Initial data from ongoing open label study of pepinemab (VX15/2503) in combination with avelumab in non-small cell lung cancer expected in 2Q 2019 Enroll.....»»
Pfizer"s (PFE) Kidney Cancer Drug Combo Gets EMA"s Validation
Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of ad.....»»